@article{0094d028475041b1ad27aacc3a22d64a,
title = "Tissue-agnostic RET inhibition: can you trust your target?",
author = "Angelica D'Aiello and Balazs Halmos",
note = "Funding Information: BH reports research funding from Boehringer Ingelheim, AstraZeneca, Merck, Bristol Myers Squibb, Advaxis, Amgen, AbbVie, Daiichi, Pfizer, GlaxoSmithKline, Beigene, and Janssen (to BH's institution), and consulting fees from AstraZeneca, Boehringer Ingelheim, Apollomics, Janssen, Takeda, Merck, Bristol Myers Squibb, Genentech, Pfizer, TPT, Arcus, and Veracyte (to BH). AD{\textquoteright}A declares no competing interests.",
year = "2022",
month = oct,
doi = "10.1016/S1470-2045(22)00556-3",
language = "English (US)",
volume = "23",
pages = "1235--1237",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Elsevier Ltd",
number = "10",
}